through a solid phase extraction device to obtain a specimen comprising separated unconjugated saccharide, i.e., solid phase extraction is used to separate the conjugated saccharide component in the sample from the unconjugated saccharide component (page 2, lines 18-20). Neither Bardotti *et al.* (*Vaccine* 18:1982-1993 (2000)) or EP 0462794) discloses a method having this step, and EP 0462794 does not relate to analysis of a sample's unconjugated saccharide content. Thus Groups I and II share a common technical special technical feature that makes a contribution over the art, and therefore are linked as to form a single general inventive concept. Accordingly, reconsideration of the requirement for restriction between Groups I and II is respectfully requested.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

## /Helen Lee/

Dated: September 26, 2010 By: \_

Helen Lee

Reg. No. 39,270

Customer No. 27476 NOVARTIS VACCINES AND DIAGNOSTICS, INC. Intellectual Property – X100B P.O. Box 8097 Emeryville, CA 94662-8097 Telephone: (510) 923-2192

Telephone: (510) 923-2192 Facsimile: (510) 655-3542